Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Enterprise Value : 14.25B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 14.25B |
| August 20, 2026 | 14.02B |
| August 19, 2026 | 14.19B |
| August 18, 2026 | 13.88B |
| August 17, 2026 | 13.66B |
| August 14, 2026 | 13.17B |
| August 13, 2026 | 13.40B |
| August 12, 2026 | 13.52B |
| August 11, 2026 | 13.62B |
| August 10, 2026 | 13.62B |
| August 07, 2026 | 13.68B |
| August 06, 2026 | 11.70B |
| August 05, 2026 | 11.45B |
| August 04, 2026 | 11.41B |
| August 03, 2026 | 11.30B |
| July 31, 2026 | 11.33B |
| July 30, 2026 | 11.42B |
| July 29, 2026 | 11.41B |
| July 28, 2026 | 11.43B |
| July 27, 2026 | 11.21B |
| July 24, 2026 | 11.26B |
| July 23, 2026 | 11.13B |
| July 22, 2026 | 10.79B |
| July 21, 2026 | 10.88B |
| July 20, 2026 | 10.71B |
| Date | Value |
|---|---|
| July 17, 2026 | 10.79B |
| July 16, 2026 | 10.76B |
| July 15, 2026 | 10.56B |
| July 14, 2026 | 10.47B |
| July 13, 2026 | 10.60B |
| July 10, 2026 | 10.61B |
| July 09, 2026 | 10.88B |
| July 08, 2026 | 11.08B |
| July 07, 2026 | 11.22B |
| July 06, 2026 | 11.13B |
| July 02, 2026 | 10.98B |
| July 01, 2026 | 10.70B |
| June 30, 2026 | 10.84B |
| June 29, 2026 | 10.97B |
| June 26, 2026 | 10.71B |
| June 25, 2026 | 10.43B |
| June 24, 2026 | 10.26B |
| June 23, 2026 | 10.08B |
| June 22, 2026 | 10.00B |
| June 18, 2026 | 9.951B |
| June 17, 2026 | 9.953B |
| June 16, 2026 | 10.08B |
| June 15, 2026 | 10.27B |
| June 12, 2026 | 10.06B |
| June 11, 2026 | 10.21B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 21.19B |
| Neurocrine Biosciences, Inc. | 15.51B |
| AVITA Medical, Inc. | 348.47M |
| Agenus, Inc. | 609.42M |
| Amgen, Inc. | 280.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 229.91M |
| Revenue (Quarterly) | 481.00M |
| Total Expenses (Quarterly) | 251.09M |
| EPS Diluted (Quarterly) | 1.897 |
| Gross Profit Margin (Quarterly) | 77.40% |
| Profit Margin (Quarterly) | 47.80% |
| Earnings Yield | 3.08% |
| Operating Earnings Yield | 7.18% |
| Normalized Earnings Yield | 5.012 |